Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of TORRENT PHARMA. For more details, see the TORRENT PHARMA quarterly results and TORRENT PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.4 |
No. of shares | m | 338.45 |
1 Week | % | -1.2 |
1 Month | % | -0.8 |
1 Year | % | 60.6 |
52 week H/L | Rs | 2,745.6/1,564.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
TORRENT PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,964 | 2,286 | 3,040 | 3,304 | 1,723 | |
Low | Rs | 1,245 | 1,453 | 1,933 | 2,478 | 1,243 | |
Sales per share (Unadj.) | Rs | 453.4 | 469.2 | 473.0 | 502.8 | 284.2 | |
Earnings per share (Unadj.) | Rs | 25.8 | 60.6 | 74.0 | 45.9 | 36.8 | |
Diluted earnings per share | Rs | 12.9 | 30.3 | 37.0 | 23.0 | 36.8 | |
Cash flow per share (Unadj.) | Rs | 62.3 | 99.2 | 112.9 | 85.1 | 57.7 | |
Dividends per share (Unadj.) | Rs | 17.00 | 32.00 | 35.00 | 48.00 | 22.00 | |
Adj. dividends per share | Rs | 8.50 | 16.00 | 17.50 | 24.00 | 22.00 | |
Avg Dividend yield | % | 1.1 | 1.7 | 1.4 | 1.7 | 1.5 | |
Book value per share (Unadj.) | Rs | 279.2 | 285.0 | 344.9 | 351.8 | 183.1 | |
Adj. book value per share | Rs | 139.6 | 142.5 | 172.5 | 175.9 | 183.1 | |
Shares outstanding (eoy) | m | 169.22 | 169.22 | 169.22 | 169.22 | 338.45 | |
Price / Sales ratio | x | 3.5 | 4.0 | 5.3 | 5.8 | 5.2 | |
Avg P/E ratio | x | 62.2 | 30.9 | 33.6 | 62.9 | 40.3 | |
P/CF ratio (eoy) | x | 25.8 | 18.8 | 22.0 | 34.0 | 25.7 | |
Price / Book Value ratio | x | 5.7 | 6.6 | 7.2 | 8.2 | 8.1 | |
Dividend payout | % | 65.9 | 52.8 | 47.3 | 104.5 | 59.8 | |
Avg Mkt Cap | Rs m | 271,518 | 316,358 | 420,798 | 489,231 | 501,779 | |
Total wages/salary | Rs m | 14,038 | 14,290 | 14,396 | 15,265 | 16,777 |
TORRENT PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 76,728 | 79,393 | 80,046 | 85,080 | 96,202 | |
Other income | Rs m | 636 | 1,213 | 569 | 1,966 | 632 | |
Total revenues | Rs m | 77,364 | 80,606 | 80,615 | 87,046 | 96,834 | |
Gross profit | Rs m | 16,195 | 21,704 | 24,801 | 19,466 | 28,240 | |
Depreciation | Rs m | 6,177 | 6,544 | 6,578 | 6,622 | 7,066 | |
Interest | Rs m | 5,038 | 4,507 | 3,529 | 2,551 | 3,334 | |
Profit before tax | Rs m | 5,617 | 11,866 | 15,263 | 12,259 | 18,472 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,254 | 1,619 | 2,744 | 4,487 | 6,019 | |
Profit after tax | Rs m | 4,363 | 10,247 | 12,519 | 7,772 | 12,452 | |
Gross profit margin | % | 21.1 | 27.3 | 31.0 | 22.9 | 29.4 | |
Effective tax rate | % | 22.3 | 13.6 | 18.0 | 36.6 | 32.6 | |
Net profit margin | % | 5.7 | 12.9 | 15.6 | 9.1 | 12.9 |
TORRENT PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 50,375 | 49,791 | 55,215 | 51,650 | 53,137 | |
Current liabilities | Rs m | 51,653 | 54,542 | 48,916 | 44,151 | 54,473 | |
Net working cap to sales | % | -1.7 | -6.0 | 7.9 | 8.8 | -1.4 | |
Current ratio | x | 1.0 | 0.9 | 1.1 | 1.2 | 1.0 | |
Inventory Days | Days | 33 | 16 | 14 | 19 | 15 | |
Debtors Days | Days | 7 | 8 | 7 | 7 | 7 | |
Net fixed assets | Rs m | 87,135 | 85,956 | 81,298 | 73,115 | 91,390 | |
Share capital | Rs m | 846 | 846 | 846 | 846 | 1,692 | |
"Free" reserves | Rs m | 46,397 | 47,386 | 57,526 | 58,683 | 60,288 | |
Net worth | Rs m | 47,244 | 48,232 | 58,372 | 59,530 | 61,981 | |
Long term debt | Rs m | 39,129 | 33,039 | 29,411 | 21,232 | 24,962 | |
Total assets | Rs m | 137,511 | 135,765 | 136,530 | 126,062 | 144,682 | |
Interest coverage | x | 2.1 | 3.6 | 5.3 | 5.8 | 6.5 | |
Debt to equity ratio | x | 0.8 | 0.7 | 0.5 | 0.4 | 0.4 | |
Sales to assets ratio | x | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | |
Return on assets | % | 6.8 | 10.9 | 11.8 | 8.2 | 10.9 | |
Return on equity | % | 9.2 | 21.2 | 21.4 | 13.1 | 20.1 | |
Return on capital | % | 12.3 | 20.1 | 21.4 | 18.3 | 25.1 | |
Exports to sales | % | 28.8 | 26.2 | 26.9 | 21.6 | 21.8 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 22,103 | 20,793 | 21,539 | 18,419 | 20,994 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 22,103 | 20,793 | 21,539 | 18,419 | 20,994 | |
Fx outflow | Rs m | 5,522 | 6,065 | 7,136 | 3,337 | 3,735 | |
Net fx | Rs m | 16,581 | 14,727 | 14,403 | 15,082 | 17,259 |
TORRENT PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 17,981 | 13,929 | 20,054 | 18,030 | 23,681 | |
From Investments | Rs m | -2,413 | 1,986 | -4,494 | -1,966 | -24,153 | |
From Financial Activity | Rs m | -13,145 | -15,490 | -16,508 | -17,811 | 774 | |
Net Cashflow | Rs m | 2,380 | 731 | -893 | -1,742 | 1,101 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: Samir Mehta | COMP SEC: Chintan Trivedi | YEAR OF INC: 1972 | BSE CODE: 500420 | FV (Rs): 5 | DIV YIELD (%): 0.9 |
Read: TORRENT PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare TORRENT PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
It was indeed a volatile trading session for Indian share markets yesterday.